MedGenome Labs launches FSHD1 genetic screening test
The FSHD1 Optical Genome Mapping Test (OGM) is a highly advanced diagnostic tool that uses cutting-edge technology
MedGenome Labs has announced the launch of Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) test in India. MedGenome Labs is the first commercial lab to offer this new genetic test that will help individuals with FSHD1 to get an early and accurate diagnosis, leading to improved disease management options.
The FSHD1 Optical Genome Mapping Test (OGM) is a highly advanced diagnostic tool that uses cutting-edge technology to provide a comprehensive and accurate assessment of genetic changes in patients with FSHD1.
Vedam Ramprasad, CEO (India), MedGenome Labs, commented on the launch, saying "As a company dedicated to improving patient care through genetics, we are thrilled to be the first in India to offer the Optical Genome Mapping Test for FSHD1. This is a significant step forward in our mission to provide the highest quality genetic testing services to clinicians and healthcare providers across the country. The launch of this new test represents a major milestone in the diagnosis and management of FSHD1 in India.”
Sakthivel Murugan SM, Vice President - Lab Operations, MedGenome Labs, said, "As a physician, I understand the challenges and concerns that patients with Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) face. With the launch of the FSHD1 test in India, we are proud to offer patients a reliable and accurate diagnostic tool that will allow for early detection and personalised treatment plans. This test is a critical step forward in advancing precision medicine in India. At MedGenome Labs, we remain committed to providing innovative solutions that address the pressing needs of our patients and the broader medical community.”
Recommended
Shearwater Health opens Chennai office
November 12, 2024
Collaborative AI Research Labs Foundation organises event in Hyderabad
November 12, 2024
Alisha Moopen bags Pravasi Bhushan Award
November 12, 2024